KennethLeeLuskeyMD

Endocrinology • Austin, TX

Diabetes, Lipid Metabolism

Physician

Join to view full profile

Dr. Luskey is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Luskey's full profile

Already have an account?

Office
4409 Balcones Drive
Austin, TX 78731

Education & Training

University of Texas Southwestern Medical CenterFellowship, Endocrinology, Diabetes, and Metabolism, 1980 - 1982
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 1976 - 1978
University of Texas Southwestern Medical SchoolClass of 1976

Certifications & Licensure

CA State Medical License 1994 - 2026
TX State Medical License 1982 - 2017
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Endocrinology, Diabetes and Metabolism

Clinical Trials

A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes Start of enrollment: 2013 Mar 01
Completed
Phase 3
A Study to Evaluate ITCA 650 Compared to Sitagliptin as add-on Therapy for the Treatment of Type 2 Diabetes Start of enrollment: 2013 May 01
Completed
Phase 3
A Study to Evaluate ITCA 650 Compared to Glimepiride for the Treatment of Type 2 Diabetes Start of enrollment: 2013 Feb 01
Withdrawn
Phase 3
A Study to Evaluate Cardiovascular Outcomes in Patients With Type 2 Diabetes Treated With ITCA 650 Start of enrollment: 2013 Mar 01
Completed
Phase 3
A Study to Evaluate ITCA 650 Compared to Sitagliptin for the Treatment of Type 2 Diabetes Start of enrollment: 2013 Feb 01
Withdrawn
Phase 3
A Study to Evaluate ITCA 650 Compared to Glimepiride as Add on Therapy for the Treatment of Type 2 Diabetes Start of enrollment: 2013 Feb 01
Withdrawn
Phase 3
Join now to see all

Publications & Presentations

PubMed

58 citations
Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 d...
Robert R. Henry, Julio Rosenstock, Douglas Logan, Thomas R. Alessi, Kenneth L. Luskey
Journal of Diabetes and Its Complications. 2014-05-01
34 citations
Randomized Trial of Continuous Subcutaneous Delivery of Exenatide by ITCA 650 Versus Twice-Daily Exenatide Injections in Metformin-Treated Type 2 Diabetes
Robert R. Henry, Julio Rosenstock, Douglas Logan, Thomas R. Alessi, Kenneth L. Luskey
Diabetes Care. 2013-09-01
5 citations
Hemorrhagic profile of the fibrinolytic alfimeprase after ischemia and reperfusion.
Aigang Lu, Yuko Kurosawa, Kenneth Luskey, Gail J. Pyne-Geithman, Danielle N. Caudell
Neurological Research. 2009-03-01

Grant Support

Amylin Expression In Normal And Diabetic StatesNational Institute Of Diabetes And Digestive And Kidney Diseases1995